Newer antiarrhythmic agents for maintaining sinus rhythm in atrial fibrillation: simplicity or complexity?
Authors:
- Bramah N. SinghBSBramah N. Singh
- Etienne AliotEAEtienne Aliot
Open Access
- 1 September 2007
- journal article
- Published by Oxford University Press (OUP) in European Heart Journal Supplements
- Vol. 9 (suppl_G) , G17-G25
Abstract
The morbidity and mortality associated with atrial fibrillation (AF), the most frequent cardiac arrhythmia, remain substantial. The efficacy and safety of current antiarrhythmic drugs continue to be less than optimal. The development of newer antiarrhythmic drugs has recently been made possible through a greater understanding of the pathophysiology of AF and knowledge of atrial electrophysiology relative to the properties of the congeners of known antiarrhythmic agents. Highly specific atrially acting drugs are currently being explored, their major merit concerning safety. In contrast, their role may be somewhat limited in view of the electrophysiological complexity of AF as an arrhythmia. The data suggest that complex antiarrhythmic agents with a multiplicity of actions may be preferable, although currently there are few data on the precise effectiveness of atrial-specific agents in maintaining sinus rhythm in AF. It is of interest that combining antiarrhythmic and non-antiarrhythmic agents, such as anti-inflammatory or antioxidant drugs, may increase the effectiveness of antifibrillatory actions in patients with AF, although these data have been obtained in uncontrolled, small or retrospective studies. Thus, at present, it is not certain whether it is preferable to target single antiarrhythmic drugs with antiadrenergic properties or to combine ‘purely’ antiarrhythmic drugs with other drugs devoid of anti-adrenergic effects. Controlled clinical trials are required to precisely define the effectiveness of single agents vs. various combinations of agents in maintaining sinus rhythm in patients with AF.Keywords
This publication has 50 references indexed in Scilit:
- Dronedarone for Maintenance of Sinus Rhythm in Atrial Fibrillation or FlutterNew England Journal of Medicine, 2007
- The Mechanism of Atrial Antiarrhythmic Action of RSD1235Journal of Cardiovascular Electrophysiology, 2005
- Amiodarone versus Sotalol for Atrial FibrillationNew England Journal of Medicine, 2005
- A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillationJACC, 2004
- The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunctionJACC, 2004
- Electrophysiologic Properties and Antiarrhythmic Actions of a Novel Antianginal AgentJournal of Cardiovascular Pharmacology and Therapeutics, 2004
- Atrial Fibrillation and StrokeStroke, 2001
- Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose-responseJACC, 2000
- Antiarrhythmic Actions of Amiodarone: A Profile of a Paradoxical AgentThe American Journal of Cardiology, 1996
- The Coming of Age of the Class III Antiarrhythmic Principle: Retrospective and Future TrendsThe American Journal of Cardiology, 1996